Targeting activity of a TCR/IL-2 fusion protein against established tumors

Cancer Immunology, Immunotherapy

Volumn 57, Issue 12, 2008, Pages 1781-1794

  Wen, Jinghai ^a   Zhu, Xiaoyun ^a   Liu, Bai ^a   You, Lijing ^a   Kong, Lin ^a   Lee, Hyung Il ^a   Han, Kai Ping ^a   Wong, Jeffrey L ^b   Rhode, Peter R ^a   Wong, Hing C ^a  

^a ALTOR BIOSCIENCE CORPORATION   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cytokines; Natural killer cells; p53; T cell receptors; Tumor immunity

Indexed keywords

ANTINEOPLASTIC AGENT; HLA A2 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; MELAN A; MELAN A T LYMPHOCYTE RECEPTOR INTERLEUKIN 2 PROTEIN; MELANOMA ANTIGEN; PROTEIN P53; T LYMPHOCYTE RECEPTOR INTERLEUKIN 2 FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; SPLEEN CELL; TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; FEMALE; FLOW CYTOMETRY; HALF-LIFE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52549111166     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0504-7     Document Type: Article

References (36)

1. MB Atkins M Regan D McDermott 2004 Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma Clin Cancer Res 10 6342S 6346S
2. JC Becker JD Pancook SD Gillies K Furukawa RA Reisfeld 1996 T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy J Exp Med 183 2361 2366
3. HJ Belmont S Price-Schiavi B Liu KF Card HI Lee KP Han J Wen S Tang X Zhu J Merrill PA Chavillaz JL Wong PR Rhode HC Wong 2006 Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein Clin Immunol 121 29 39
4. KF Card SA Price-Schiavi B Liu E Thomson E Nieves H Belmont J Builes JA Jiao J Hernandez J Weidanz L Sherman JL Francis A Amirkhosravi HC Wong 2004 A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity Cancer Immunol Immunother 53 345 357
5. DZ Chang Z Wu TL Ciardelli 1996 A point mutation in interleukin-2 that alters ligand internalization J Biol Chem 271 13349 13355
6. O Christ S Seiter S Matzku C Burger M Zoller 2001 Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy Clin Cancer Res 7 985 998
7. JS Dela Cruz TH Huang ML Penichet SL Morrison 2004 Antibody-cytokine fusion proteins: innovative weapons in the war against cancer Clin Exp Med 4 57 64
8. C Demaison L Fiette V Blanchetiere A Schimpl J Theze P Froussard 1998 IL-2 receptor {alpha}-chain expression is independently regulated in primary and secondary lymphoid organs J Immunol 161 1977 1982
9. JM Depper WJ Leonard C Drogula M Kronke TA Waldmann WC Greene 1985 Interleukin 2 (IL-2) Augments transcription of the IL-2 receptor gene PNAS 82 4230 4234
10. ME Dudley JR Wunderlich JC Yang RM Sherry SL Topalian NP Restifo RE Royal U Kammula DE White SA Mavroukakis LJ Rogers GJ Gracia SA Jones DP Mangiameli MM Pelletier J Gea-Banacloche MR Robinson DM Berman AC Filie A Abati SA Rosenberg 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2346 2357
11. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1841
12. TK Hoffmann K Nakano EM Elder G Dworacki SD Finkelstein E Appella TL Whiteside AB DeLeo 2000 Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants J Immunol 165 5938 5944
13. C Jackaman CS Bundell BF Kinnear AM Smith P Filion D van Hagen BW Robinson DJ Nelson 2003 IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2 J Immunol 171 5051 5063
14. LA Johnson B Heemskerk DJ Powell Jr CJ Cohen RA Morgan ME Dudley PF Robbins SA Rosenberg 2006 Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes J Immunol 177 6548 6559
15. E Lavergne B Combadiere O Bonduelle M Iga JL Gao M Maho A Boissonnas PM Murphy P Debre C Combadiere 2003 Fractalkine mediates natural killer-dependent antitumor responses in vivo Cancer Res 63 7468 7474
16. AJ Levine J Momand CA Finlay 1991 The p53 tumour suppressor gene Nature 351 453 456
17. HN Lode R Xiang T Dreier NM Varki SD Gillies RA Reisfeld 1998 Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood 91 1706 1715
18. J Lustgarten J Marks LA Sherman 1999 Redirecting effector T cells through their IL-2 receptors J Immunol 162 359 365
19. RJ Melder BL Osborn T Riccobene P Kanakaraj P Wei G Chen D Stolow WG Halpern TS Migone Q Wang KJ Grzegorzewski G Gallant 2005 Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice Cancer Immunol Immunother 54 535 547
20. JS Miller Y Soignier A Panoskaltsis-Mortari SA McNearney GH Yun SK Fautsch D McKenna C Le TE Defor LJ Burns PJ Orchard BR Blazar JE Wagner A Slungaard DJ Weisdorf IJ Okazaki PB McGlave 2005 Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 3051 3057
21. LA Mosquera KF Card SA Price-Schiavi HJ Belmont B Liu J Builes X Zhu PA Chavaillaz HI Lee JA Jiao JL Francis A Amirkhosravi RL Wong HC Wong 2005 In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein J Immunol 174 4381 4388
22. BH Nelson DM Willerford 1998 Biology of the interleukin-2 receptor Adv Immunol 70 1 81
23. RK Puri WD Travis SA Rosenberg 1990 In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice Cancer Res 50 5543 5550
24. P Radny UM Caroli J Bauer T Paul C Schlegel TK Eigentler B Weide M Schwarz C Garbe 2003 Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases Br J Cancer 89 1620 1626
25. RJ Robb WC Greene 1987 Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor J Exp Med 165 1201 1206
26. SA Rosenberg MT Lotze LM Muul AE Chang FP Avis S Leitman WM Linehan CN Robertson RE Lee JT Rubin 1987 A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 316 889 897
27. J Running Deer DS Allison 2004 High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene Biotechnol Prog 20 880 889
28. S Strano S Dell'Orso S Di Agostino G Fontemaggi A Sacchi G Blandino 2007 Mutant p53: an oncogenic transcription factor Oncogene 26 2212 2219
29. AA Tarhini SS Agarwala 2005 Interleukin-2 for the treatment of melanoma Curr Opin Investig Drugs 6 1234 1239
30. JA Toomey F Gays D Foster CG Brooks 2003 Cytokine requirements for the growth and development of mouse NK cells in vitro J Leukoc Biol 74 233 242
31. SD Voss RJ Robb G Weil-Hillman JA Hank K Sugamura M Tsudo PM Sondel 1990 Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding J Exp Med 172 1101 1114
32. R Xiang HN Lode CS Dolman T Dreier NM Varki X Qian KM Lo Y Lan M Super SD Gillies RA Reisfeld 1997 Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy Cancer Res 57 4948 4955
33. X Xu P Clarke G Szalai JE Shively LE Williams Y Shyr E Shi FJ Primus 2000 Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein Cancer Res 60 4475 4484
34. YR Yu AM Fong C Combadiere JL Gao PM Murphy DD Patel 2007 Defective antitumor responses in CX3CR1-deficient mice Int J Cancer 121 316 322
35. Y Zhai JC Yang Y Kawakami P Spiess SC Wadsworth LM Cardoza LA Couture AE Smith SA Rosenberg 1996 Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy J Immunol 156 700 710
36. X Zhu HJ Belmont S Price-Schiavi B Liu HI Lee M Fernandez RL Wong J Builes PR Rhode HC Wong 2006 Visualization of p53(264-272)/HLA-A*0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor J Immunol 176 3223 3232